IMM Insider Trading (ImmuPharma)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £10,000
Insider Selling (Last 12 Months): GBX 0
ImmuPharma Share Price & Price History
Current Price: GBX 5.17
Price Change: +0.30 (1.20%)
As of 08/12/2022 01:00 AM ET
The Safest Option in Trades!
From Tradewins | Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
ImmuPharma Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
8/24/2021 | Sanjeev Pandya | Insider | Buy | 125,000 | GBX 8 | £10,000 | | |
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
SEC Filings (Institutional Ownership Changes) for ImmuPharma (LON:IMM)
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Read More on ImmuPharma
Today's Range
Now: GBX 5.17
50 Day Range
MA: GBX 5.78
52 Week Range
Now: GBX 5.17
Volume
1,532,677 shs
Average Volume
1,137,458 shs
Market Capitalization
£14.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of ImmuPharma?